A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine

• Published in: Cancer chemotherapy and pharmacology Vol. 16; no. 3; pp. 207 - 210
• Main Authors: GAVER, R. C, DIXON, C. W, SMYTH, R. D
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01-04-1986
• Subjects: Analysis; Animals; Biological and medical sciences; Bleomycin - analysis; Bleomycin - blood; Bleomycin - urine; Cross Reactions; General pharmacology; Humans; Iodine Radioisotopes; Medical sciences; Pharmacology. Drug treatments; Rabbits; Radioimmunoassay; Antineoplastic agent; Assay; Urine; Antibiotic; Glycopeptide; Radioimmunoassay; Immunological method; Blood plasma
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/BF00293979

A simple and sensitive radioimmunoassay (RIA) procedure was developed and validated for the analysis of tallysomycin S10b in human plasma and urine. The assay utilized antisera developed in rabbits, 125I-tallysomycin as the radioligand, and dextran-coated charcoal to separate free and bound antigen. The antibody was specific in that it did not cross-react with either tallysomycin A or bleomycin. The lower limit of quantification was 5 ng per ml plasma or urine, and the linear range of the assay was 5-320 ng tallysomycin S10b base per ml plasma or urine. The within-day assay variability (%RSD) for plasma and urine was 11% at a concentration of 50 ng per ml, and 3% and 7% for plasma and urine, respectively at 200 ng per ml. Within-day accuracy ranged from 100% to 108% of the theoretical value. Tallysomycin S10b was stable in human plasma and urine at concentrations of 20 and 160 ng per ml for at least 7 months when stored at -20 degrees C. The method was applied to the analysis of plasma and urine samples from a patient given tallysomycin S10b as part of a phase I study.